New and better information for scientists, toward novel therapeutic strategies in cancer and congenital disorders. We design, we produce and we provide research tools for gene expression analysis at the ribosomal level
We are engaged with customers at every step of the way.
IMMAGINA BioTechnology s.r.l (The Ribosome Company) is a company operating in the MedTech sector of Genomics, Proteomics and Enabling Technology, that is incubated in the Laboratory for Biomolecular Sequence and Structure Analysis for Health in Trento (Italy). Our mission is to deliver high-quality solutions to assess translational control of gene expression and translatome-associated biomarkers.
IMMAGINA was founded in 2014, when the founder (Dr. Massimiliano Clamer) started to develop RiboLaceTM, the only technology that enable the capture of active ribosomes.
RiboLace is on the market from November 2018. Starting from 2016, thanks to the levering investments from private investors (of whom the most relevant one is BAN/TN, TBA network and the Herman Hauser Investment) and the recruitment of new experienced scientists, two new technologies for translatome analysis (AHARIBOTM and circAID-p-seqTM) were developed and finally launched on the market at the end of 2019.
IMMAGINA offers a platform of products with the potential to accelerate the path toward the discovery of novel therapeutic strategies.
We deliver high-quality solutions to assess translational control of gene expression and translatome-associated biomarkers.
The Ribosome Company
IMMAGINA designed, developed and commercialize a Platform Technology focused on Ribosome to isolate and analyse active ribosomes and the associated RNA molecules
IMMAGINA ambition is to deliver smart solutions for truer gene expression analysis in research and pharma labs, to support life science worldwide. We are working to provide you with the best picture of gene expression. Because the message is only part of the story.
Wants to join the startup company to help accomplish our mission?